keyword
MENU ▼
Read by QxMD icon Read
search

Xtandi

keyword
https://www.readbyqxmd.com/read/27900064/enzalutamide-induced-acute-generalized-exanthematous-pustulosis
#1
Chloé Alberto, Maria Polina Konstantinou, Catherine Martinage, Eline Casassa, Emilie Tournier, Haleh Bagheri, Vincent Sibaud, Loïc Mourey, Juliette Mazereeuw-Hautier, Nicolas Meyer, Carle Paul, Cristina Bulai Livideanu
INTRODUCTION: Enzalutamide (Xtandi®) is a new potent inhibitor of the signaling pathway for the androgen receptor with a half-life of 5.8 days. It has been on the market for the treatment of metastatic castration-resistant prostate cancer since November 2013. OBJECTIVE: We report the first case of acute generalized exanthematous pustulosis (AGEP) induced by enzalutamide. OBSERVATION: A 62-year-old male patient with no significant medical history, was diagnosed in April 2014 with metastatic prostatic adenocarcinoma...
November 13, 2016: Journal of Dermatological Case Reports
https://www.readbyqxmd.com/read/27119752/current-advances-in-intratumoral-androgen-metabolism-in-castration-resistant-prostate-cancer
#2
Trevor M Penning, Daniel Tamae
PURPOSE OF REVIEW: Androgen deprivation therapy is a cornerstone in the treatment of advanced prostate cancer and has extended the lives of countless patients. Unfortunately, many of these patients eventually succumb to metastatic castration-resistant prostate cancer (mCRPC). The efficacy of abiraterone acetate (AA, Zytiga) and enzalutamide (Enza, Xtandi) in the mCRPC setting prove that these tumors remain androgen-driven. We review recent studies that have shown that intratumoral androgen biosynthesis plays a significant role in the ever-evolving mCRPC tumor and we discuss the therapeutic implications of these findings...
June 2016: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/26814148/mechanisms-of-resistance-in-castration-resistant-prostate-cancer-crpc
#3
REVIEW
Thenappan Chandrasekar, Joy C Yang, Allen C Gao, Christopher P Evans
Despite advances in prostate cancer diagnosis and management, morbidity from prostate cancer remains high. Approximately 20% of men present with advanced or metastatic disease, while 29,000 men continue to die of prostate cancer each year. Androgen deprivation therapy (ADT) has been the standard of care for initial management of advanced or metastatic prostate cancer since Huggins and Hodges first introduced the concept of androgen-dependence in 1972, but progression to castration-resistant prostate cancer (CRPC) occurs within 2-3 years of initiation of ADT...
June 2015: Translational Andrology and Urology
https://www.readbyqxmd.com/read/26583636/navigating-treatment-of-metastatic-castration-resistant-prostate-cancer-nursing-perspectives
#4
Frank dela Rama, Caroline Pratz
BACKGROUND: Treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved rapidly. In particular, five new treatments that extend survival in mCRPC have been approved since 2010, including the chemotherapy cabazitaxel (Jevtana®), hormonal agents abiraterone (Zytiga®) and enzalutamide (Xtandi®), vaccine sipuleucel-T (Provenge®), and radiopharmaceutical radium-223 (Xofigo®); all have different indications and toxicity profiles. OBJECTIVES: This review discusses treatment advances in mCRPC, including considerations for side-effect management and treatment sequencing...
December 2015: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/25945058/enzalutamide-for-patients-with-metastatic-castration-resistant-prostate-cancer
#5
REVIEW
Wijdan H Ramadan, Wissam K Kabbara, Hiba S Al Basiouni Al Masri
OBJECTIVE: To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. DATA SOURCES: Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and castration-resistant prostate cancer. Data from FDA product labels were also used. STUDY SELECTION AND DATA EXTRACTION: Recent and relevant studies were included in the review...
2015: OncoTargets and Therapy
https://www.readbyqxmd.com/read/25711765/enzalutamide-a-review-of-its-use-in-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer
#6
REVIEW
Gillian M Keating
Enzalutamide (Xtandi(®)) is an androgen receptor inhibitor that blocks several steps in the androgen receptor signalling pathway. This article reviews the clinical efficacy and tolerability of oral enzalutamide in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC), as well as summarizing its pharmacological properties. In the randomized, double-blind, multinational PREVAIL trial, enzalutamide significantly improved both radiographic progression-free survival and overall survival versus placebo in chemotherapy-naïve men with metastatic CRPC who were asymptomatic or mildly symptomatic...
March 2015: Drugs & Aging
https://www.readbyqxmd.com/read/25534660/enzalutamide-versus-abiraterone-acetate-for-the-treatment-of-men-with-metastatic-castration-resistant-prostate-cancer
#7
REVIEW
Tian Zhang, Jason Zhu, Daniel J George, Andrew J Armstrong
INTRODUCTION: Over the past decade, treatment options for men with metastatic castration-resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate (AA), enzalutamide, sipuleucel-T, radium-223, docetaxel and cabazitaxel. The optimal sequencing of therapies in the context of efficacy and known cross-resistance remains uncertain. AREAS COVERED: We review the development of enzalutamide (MDV3100, Xtandi), a novel second-generation androgen receptor (AR), and AA (Zytiga), a selective, irreversible inhibitor of cytochrome P17...
March 2015: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/24494031/preclinical-development-of-onc1-13b-novel-antiandrogen-for-prostate-cancer-treatment
#8
Alexandre V Ivachtchenko, Oleg D Mitkin, Elizaveta V Kudan, Alexey A Rjahovsky, Anton A Vorobiev, Andrey S Trifelenkov, Natalia A Shevkun, Oxana V Proskurina, Dmitry V Kravchenko, Ruben N Karapetian
Recently new drugs targeting androgen-dependent axis have been approved for the treatment of castration-resistant prostate cancer (CRPC) - Zytiga and Xtandi (formerly MDV3100), several other candidates (for example, ARN-509) are in early phases of clinical trials. However despite significant improvement in overall survival with new treatments it is evident that resistance to these drugs develops. One of the approaches to overcome it is combination therapy and from this point of view some potential for drug-drug interactions can limit the application of the drug...
2014: Journal of Cancer
https://www.readbyqxmd.com/read/24458946/enzalutamide-xtandi-for-patients-with-metastatic-resistant-prostate-cancer
#9
REVIEW
Lunawati L Bennett, April Ingason
OBJECTIVE: To review the pharmacology and pharmacokinetics, and to evaluate the clinical efficacy, safety, and place in therapy of enzalutamide for the treatment of castration-resistant prostate cancer (CRPC). DATA SOURCES: A literature search through PubMed (1984 to November 2013; English language) was performed using the following keywords: MDV3100, androgen deprivation therapy, enzalutamide, CRPC, and androgen receptor antagonist. Searches were limited to published studies in humans...
April 2014: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/24141628/enzalutamide-for-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer-who-have-previously-received-docetaxel-u-s-food-and-drug-administration-drug-approval-summary
#10
Yangmin M Ning, William Pierce, V Ellen Maher, Stella Karuri, Sheng-Hui Tang, Haw-Jyh Chiu, Todd Palmby, Jeanne Fourie Zirkelbach, Dhananjay Marathe, Nitin Mehrotra, Qi Liu, Debasis Ghosh, Christy L Cottrell, John Leighton, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur
This article summarizes the regulatory evaluation that led to the full approval of enzalutamide (XTANDI, Medivation Inc.) by the U.S. Food and Drug Administration (FDA) on August 31, 2012, for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. This approval was based on the results of a randomized, placebo-controlled trial which randomly allocated 1,199 patients with mCRPC who had received prior docetaxel to receive either enzalutamide, 160 mg orally once daily (n = 800), or placebo (n = 399)...
November 15, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/24127223/enzalutamide-a-review-of-its-use-in-metastatic-castration-resistant-prostate-cancer
#11
REVIEW
Mark Sanford
Enzalutamide (MDV3100, XTANDI(®)) is an androgen receptor inhibitor that is indicated for the treatment of metastatic, castration-resistant, prostate cancer (mCRPC) that has progressed despite treatment with docetaxel. This article reviews the pharmacology, efficacy and tolerability of enzalutamide relevant to this indication. In a randomized, double-blind, placebo-controlled, multinational, phase III trial in patients with mCRPC progressing after docetaxel therapy, enzalutamide significantly prolonged overall survival (OS), delayed prostate specific antigen progression and prolonged radiographic progression-free survival and time to the first skeletal event...
October 2013: Drugs
https://www.readbyqxmd.com/read/23765603/enzalutamide-an-androgen-receptor-signaling-inhibitor-induces-tumor-regression-in-a-mouse-model-of-castration-resistant-prostate-cancer
#12
Javier Guerrero, Iván E Alfaro, Francisco Gómez, Andrew A Protter, Sebastián Bernales
BACKGROUND: Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: binding of androgens to AR, AR nuclear translocation, and association of AR with DNA. Here, we investigate the effects of enzalutamide on AR signaling, AR-dependent gene expression and cell apoptosis...
September 2013: Prostate
https://www.readbyqxmd.com/read/23701654/enzalutamide-a-novel-anti-androgen-with-prolonged-survival-rate-in-crpc-patients
#13
REVIEW
Richa Dhingra, Tina Sharma, Sukhminder Singh, Shivani Sharma, Prince Tomar, Manav Malhotra, T R Bhardwaj
Prostate cancer is the most common malignancy among men found to be the second leading cause of male cancer-related mortality due to development of resistance against androgen deprivation therapy (ADT). With the advancement in understanding of prostate cancer, numbers of agents have been emerged to target Androgen-Receptor (AR) signaling for the treatment of castration resistant prostate cancer (CRPC). Food and Drug Administration (FDA) has recently approved enzalutamide (XTANDI) for the treatment of CRPC. Androgen receptor promotes the prostate cancer progression after transformation...
August 2013: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/23467121/enzalutamide-xtandi-for-prostate-cancer
#14
(no author information available yet)
No abstract text is available yet for this article.
March 4, 2013: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/23300275/enzalutamide-a-novel-antiandrogen-for-patients-with-castrate-resistant-prostate-cancer
#15
RANDOMIZED CONTROLLED TRIAL
Jean Hoffman-Censits, Wm Kevin Kelly
Enzalutamide (MDV3100, Xtandi, Medivation\Astellas) is an oral inhibitor of androgen receptor signaling that blocks androgen receptor interaction, inhibits translocation of the androgen receptor to the nucleus, impairs androgen receptor binding to DNA, and inhibits coactivator recruitment and receptor-mediated DNA transcription. In a phase III randomized study comparing enzalutamide with placebo in men with progressive castration-resistant prostate cancer (CRPC) who were previously treated with docetaxel, enzalutamide showed an improvement in overall survival (18...
March 15, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/23115463/pharmaceutical-approval-update
#16
Marvin M Goldenberg
Truvada for HIV prevention, Xtandi for metastatic castration-resistant prostate cancer, and Marqibo, a vincristine liposome injection for acute myelogenous leukemia.
October 2012: P & T: a Peer-reviewed Journal for Formulary Management
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"